🎉 M&A multiples are live!
Check it out!

Affimed Valuation Multiples

Discover revenue and EBITDA valuation multiples for Affimed and similar public comparables like Pharming, Vivoryon Therapeutics, and Julphar.

Affimed Overview

About Affimed

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.


Founded

2014

HQ

United States of America
Employees

78

Website

affimed.com

Financials

LTM Revenue $11.7M

LTM EBITDA n/a

EV

-$0.7M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Affimed Financials

Affimed has a last 12-month revenue of $11.7M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Affimed achieved revenue of $8.3M and an EBITDA of -$102M.

Affimed expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Affimed valuation multiples based on analyst estimates

Affimed P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $41.4M $8.3M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$81.5M -$102M XXX XXX XXX
EBITDA Margin -197% -1237% XXX XXX XXX
Net Profit -$57.5M -$86.0M XXX XXX XXX
Net Margin -139% -1039% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Affimed Stock Performance

As of April 15, 2025, Affimed's stock price is $1.

Affimed has current market cap of $13.0M, and EV of -$0.7M.

See Affimed trading valuation data

Affimed Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$0.7M $13.0M XXX XXX XXX XXX $-3.81

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Affimed Valuation Multiples

As of April 15, 2025, Affimed has market cap of $13.0M and EV of -$0.7M.

Affimed's trades at -0.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Affimed's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Affimed and 10K+ public comps

Affimed Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$0.7M XXX XXX XXX
EV/Revenue -0.1x XXX XXX XXX
EV/EBITDA 0.0x XXX XXX XXX
P/E -0.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Affimed Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Affimed Valuation Multiples

Affimed's NTM/LTM revenue growth is 109%

Affimed's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.5M for the same period.

Over next 12 months, Affimed's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Affimed's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Affimed and other 10K+ public comps

Affimed Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -80% XXX XXX XXX XXX
EBITDA Margin -1237% XXX XXX XXX XXX
EBITDA Growth 26% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -1128% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 298% XXX XXX XXX XXX
R&D Expenses to Revenue 1148% XXX XXX XXX XXX
Opex to Revenue 1443% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Affimed Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Affimed M&A and Investment Activity

Affimed acquired  XXX companies to date.

Last acquisition by Affimed was  XXXXXXXX, XXXXX XXXXX XXXXXX . Affimed acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Affimed

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Affimed

When was Affimed founded? Affimed was founded in 2014.
Where is Affimed headquartered? Affimed is headquartered in United States of America.
How many employees does Affimed have? As of today, Affimed has 78 employees.
Who is the CEO of Affimed? Affimed's CEO is Dr. Andreas Harstrick, M.D..
Is Affimed publicy listed? Yes, Affimed is a public company listed on NAS.
What is the stock symbol of Affimed? Affimed trades under AFMD ticker.
When did Affimed go public? Affimed went public in 2014.
Who are competitors of Affimed? Similar companies to Affimed include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Affimed? Affimed's current market cap is $13.0M
What is the current revenue of Affimed? Affimed's last 12-month revenue is $11.7M.
What is the current EV/Revenue multiple of Affimed? Current revenue multiple of Affimed is -0.1x.
What is the current revenue growth of Affimed? Affimed revenue growth between 2023 and 2024 was -80%.
Is Affimed profitable? Yes, Affimed is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.